Jefferies Assumes Corcept Therapeutics (CORT), Upgrades to Buy

July 27, 2022 7:50 AM EDT
Get Alerts CORT Hot Sheet
Price: $24.98 +0.16%

Rating Summary:
    9 Buy, 6 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 2 | Down: 23 | New: 24
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Jefferies analyst Dennis Ding assumes coverage on Corcept Therapeutics (NASDAQ: CORT) with a Buy rating (from Neutral) and a price target of $35.00.

The analyst comments "Assuming and upgrading CORT to BUY and $35 PT on an interesting defensive yet offensive healthcare story over the next few years. We think CORT should benefit in the current challenging macro environment since the $400M+ Cushing's base biz is high margin, profitable, and FCF generating, which is attractive among SMID cap biotech peers. Pipeline readouts over the next few years should drive an improved top and bottom-line growth profile through the decade."

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $26.81 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage, Upgrades

Related Entities

Jefferies & Co